La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Guangzhou Baiyunshan Pharmaceutical Holdings Gestion
Gestion contrôle des critères 4/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Hong Li
Directeur général
CN¥1.5m
Rémunération totale
| Pourcentage du salaire du PDG | 30.6% |
| Durée du mandat du directeur général | 7.2yrs |
| Propriété du PDG | n/a |
| Durée moyenne d'occupation des postes de direction | 7.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.8yrs |
Mises à jour récentes de la gestion
The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23
Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26Recent updates
A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥2m | CN¥471k | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥460k | CN¥4b |
| Sep 30 2022 | n/a | n/a | CN¥4b |
| Jun 30 2022 | n/a | n/a | CN¥4b |
| Mar 31 2022 | n/a | n/a | CN¥4b |
| Dec 31 2021 | CN¥2m | CN¥456k | CN¥4b |
| Sep 30 2021 | n/a | n/a | CN¥4b |
| Jun 30 2021 | n/a | n/a | CN¥4b |
| Mar 31 2021 | n/a | n/a | CN¥3b |
| Dec 31 2020 | CN¥1m | CN¥442k | CN¥3b |
| Sep 30 2020 | n/a | n/a | CN¥3b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥3b |
| Dec 31 2019 | CN¥1m | CN¥428k | CN¥3b |
| Sep 30 2019 | n/a | n/a | CN¥3b |
| Jun 30 2019 | n/a | n/a | CN¥3b |
| Mar 31 2019 | n/a | n/a | CN¥4b |
| Dec 31 2018 | CN¥1m | CN¥382k | CN¥3b |
Rémunération vs marché: La rémunération totale de Hong ($USD 215.63K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 913.61K ).
Rémunération et revenus: La rémunération de Hong a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Hong Li (57 yo)
7.2yrs
Titularisation
CN¥1,539,030
Compensation
Mr. Hong Li has been General Manager at Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited since June 23, 2017 and serves as its Executive Director since June 22, 2018. Mr. Li started his career...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| GM & Executive Director | 7.2yrs | CN¥1.54m | pas de données | |
| Executive Vice Chairman | 11.9yrs | pas de données | pas de données | |
| Executive Vice Chairman | 4.6yrs | pas de données | pas de données | |
| Deputy GM & Executive Director | 9.6yrs | CN¥1.57m | pas de données | |
| Executive Director | no data | pas de données | pas de données | |
| Executive Director | 8.6yrs | CN¥1.56m | pas de données | |
| Deputy GM & Director of Business Administration Department | 5.1yrs | CN¥1.41m | pas de données | |
| Secretary | 7.3yrs | CN¥1.24m | pas de données |
7.3yrs
Durée moyenne de l'emploi
55.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de 874 est chevronnée et expérimentée (ancienneté moyenne 7.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| GM & Executive Director | 6.2yrs | CN¥1.54m | pas de données | |
| Executive Vice Chairman | 11.9yrs | pas de données | pas de données | |
| Executive Vice Chairman | 4.6yrs | pas de données | pas de données | |
| Deputy GM & Executive Director | 14.2yrs | CN¥1.57m | pas de données | |
| Executive Director | 10.6yrs | pas de données | pas de données | |
| Executive Director | 5.2yrs | CN¥1.56m | pas de données | |
| Independent Non-Executive Director | 1.3yrs | CN¥50.00k | pas de données | |
| Chairman of the Supervisory Board | 4.9yrs | pas de données | pas de données | |
| Supervisor | 4.6yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 4.2yrs | CN¥120.00k | pas de données | |
| Independent Non-Executive Director | 4.2yrs | CN¥120.00k | pas de données | |
| Independent Non-Executive Director | 1.3yrs | pas de données | pas de données |
4.8yrs
Durée moyenne de l'emploi
57.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de 874 sont considérés comme expérimentés (ancienneté moyenne 4.8 ans).